Hepatitis Weekly
Susan Hasty, Publisher
Table of Contents . . . October 24th, 2005
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Hepatitis Weekly | Other Publications
Diagnostics - Phased screening uncovers the antiviral activity of hepatitis C virus therapy
Hepatitis B Therapy - C-13-caffeine breath test detects chronic hepatitis B response to lamivudine
Hepatitis B Therapy - RNA interference fights hepatitis B virus replication in murine models
Hepatitis C Therapy - Serum alpha-fetoprotein levels decline in patients who receive hepatitis C virus therapy
Adverse Drug Reaction - Drugs raise mitochondrial toxicity risk in HIV/hepatitis C-coinfected patients
Alcohol Use - S-adenosylmethionine averts liver cancer growth in alcohol hepatitis models
Cancer Risk Factors - Hepatitis C virus may account for some cases of splenic large B-cell lymphoma
Cardiology - Findings in cardiology provide new insights
Chronic Hepatitis C - Patients with hepatitis C infection accumulate 8-nitroguanine in the liver
Chronic Hepatitis C - Virological response to hepatitis C virus therapy is apparent within 12 weeks
Oncology - Researchers detail new studies and findings in the area of oncology
Clinical Trials - First monotherapy clinical study of celgosivir in chronic hepatitis C completed
Diagnostics - Angiogenesis soluble markers may diagnose chronic hepatitis C progression
Diagnostics - Findings advance knowledge in diagnostics research
Diagnostics - MxA promoter activation monitors interferon activity in patients with hepatitis
Drug Abuse - Injection drug use-related hepatitis C infection generates parenchymal injury
Drug Abuse - Substance abuse recovery center receives $1.7 million grant
Drug Development - Biopharma to appeal Nasdaq delisting letter
Drug Development - Hepatitis drug development data to be presented at liver disease meeting
Drug Development - Isatoribine lowers plasma hepatitis C RNA in chronically infected patients
Drug Development - Manufacturing relationship established to develop monoclonal antibodies targeting HBV
Generic Drugs - U.S. FDA grants tentative approval of ANDA for ribavirin tablets for HCV
Healthcare Practice - Experts differ on the management of patients with chronic hepatitis C
Hepatitis A Prevention - Few patients with chronic hepatitis C are protected against hepatitis A infection
Hepatitis A Virus - Outbreak of hepatitis A associated with green onions
Hepatitis C Complications - Hepatitis C drug is cost-effective for treatment-induced anemia
Hepatitis C Therapy - Enzyme predicts hepatitis C virus response to antiviral therapy
Hepatitis C Therapy - Small hairpin RNAs control hepatitis C virus infection in murine and human cells
Hepatitis C Therapy - Synergy between antivirals and antioxidants benefits patients with chronic hepatitis C
Hepatitis C Virus - Liver-specific microRNA modulates hepatitis C virus replication
Hepatitis C Virus - Positive preliminary results announced for phase I/II trial of IFN-alpha-XL
Hepatitis C Virus - Results from pilot project to identify hepatitis C sufferers announced
Hepatitis C Virus - Second phase Ib clinical study of Actilon for treatment of HCV begins
Hepatitis C Virus - Viperin is an antiviral effector in liver cell cultures
Hepatocellular Carcinoma - Aflatoxins exacerbate the risk for hepatitis B-related liver cancer
Hepatocellular Carcinoma - Sustained response to hepatitis C therapy extends survival after liver tumor ablation
Liver Cirrhosis - Early initiation of lamivudine helps patients with hepatitis B-related decompensated cirrhosis
Liver Disease - A high fat diet alters hepatic immune system in mice
Obstetrics - Vertical exposure to hepatitis C endows infants with virus-specific protection
Oncology - Research in oncology provides new insights
Patents - U.K. patent granted broadly covering RNAi-mediated inhibition of gene expression
Product Branding - Tolamba, Heplisav are brand names for allergy and hepatitis products
Product Licensing - License, asset purchase agreement with VivoQuest for intellectual property and technology announced
Stem Cell Research - Epithelial membrane protein-1 is a junctional protein in the liver
Transplant Medicine - Biomarkers used to predict recurrent disease in hepatitis C transplant patients
Transplant Medicine - Recent studies add new data to transplant medicine research
Transplant Medicine - Test predicts risk of liver scarring after transplant
Virology - Hepatitis C virus replication strengthens upon CD8+ T cell depletion
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
